Sacco, R. L. et al. An updated definition of stroke for the 21st century: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44(7), 2064–2089 (2013).
Campbell, B. C. V. et al. Ischaemic stroke. Nat. Rev. Dis. Primers 5(1), 70 (2019).
Patel, P., Yavagal, D. & Khandelwal, P. Hyperacute management of ischemic strokes: JACC focus seminar. J. Am. Coll. Cardiol. 75(15), 1844–1856 (2020).
Agostini, M., Melino, G. & Bernassola, F. The p53 family in brain disease. Antioxid. Redox Signal. 29(1), 1–14 (2018).
Miller, F. D., Pozniak, C. D. & Walsh, G. S. Neuronal life and death: An essential role for the p53 family. Cell Death Differ. 7(10), 880–888 (2000).
Li, Y. et al. p53-immunoreactive protein and p53 mRNA expression after transient middle cerebral artery occlusion in rats. Stroke 25(4), 849–855 (1994) (discussion 55–6).
Filichia, E. et al. Forebrain neuronal specific ablation of p53 gene provides protection in a cortical ischemic stroke model. Neuroscience 295, 1–10 (2015).
Turnquist, C. et al. p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration. Cell Death Differ. 23(9), 1515–1528 (2016).
Vaseva, A. V. et al. p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell 149(7), 1536–1548 (2012).
Sedarous, M. et al. Calpains mediate p53 activation and neuronal death evoked by DNA damage. J. Biol. Chem. 278(28), 26031–26038 (2003).
Leker, R. R., Aharonowiz, M., Greig, N. H. & Ovadia, H. The role of p53-induced apoptosis in cerebral ischemia: Effects of the p53 inhibitor pifithrin alpha. Exp. Neurol. 187(2), 478–486 (2004).
Niizuma, K., Endo, H., Nito, C., Myer, D. J. & Chan, P. H. Potential role of PUMA in delayed death of hippocampal CA1 neurons after transient global cerebral ischemia. Stroke 40(2), 618–625 (2009).
Feng, X., Liu, X., Zhang, W. & Xiao, W. p53 directly suppresses BNIP3 expression to protect against hypoxia-induced cell death. EMBO J. 30(16), 3397–3415 (2011).
Wang, X. et al. Intervention of death-associated protein kinase 1–p53 interaction exerts the therapeutic effects against stroke. Stroke 45(10), 3089–3091 (2014).
Zhang, T. et al. MALAT1 activates the P53 signaling pathway by regulating MDM2 to promote ischemic stroke. Cell Physiol. Biochem. 50(6), 2216–2228 (2018).
Haupt, S. et al. Targeting Mdmx to treat breast cancers with wild-type p53. Cell Death Dis. 6, e1821 (2015).
Saito, A., Hayashi, T., Okuno, S., Nishi, T. & Chan, P. H. Modulation of p53 degradation via MDM2-mediated ubiquitylation and the ubiquitin-proteasome system during reperfusion after stroke: Role of oxidative stress. J. Cereb. Blood Flow Metab. 25(2), 267–280 (2005).
Vecino, R. et al. The MDM2–p53 pathway is involved in preconditioning-induced neuronal tolerance to ischemia. Sci. Rep. 8(1), 1610 (2018).
Wade, M., Li, Y. C. & Wahl, G. M. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat. Rev. Cancer 13(2), 83–96 (2013).
Karni-Schmidt, O., Lokshin, M. & Prives, C. The roles of MDM2 and MDMX in cancer. Annu. Rev. Pathol. 11, 617–644 (2016).
Miles, X., Vandevoorde, C., Hunter, A. & Bolcaen, J. MDM2/X inhibitors as radiosensitizers for glioblastoma targeted therapy. Front. Oncol. 11, 703442 (2021).
Pant, V., Xiong, S., Iwakuma, T., Quintas-Cardama, A. & Lozano, G. Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc. Natl. Acad. Sci. U.S.A. 108(29), 11995–12000 (2011).
Huang, L. et al. The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Proc. Natl. Acad. Sci. U.S.A. 108(29), 12001–12006 (2011).
Parant, J. et al. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat. Genet. 29(1), 92–95 (2001).
Xiong, S., Van Pelt, C. S., Elizondo-Fraire, A. C., Liu, G. & Lozano, G. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc. Natl. Acad. Sci. U.S.A. 103(9), 3226–3231 (2006).
Francoz, S. et al. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc. Natl. Acad. Sci. U.S.A. 103(9), 3232–3237 (2006).
Polager, S. & Ginsberg, D. p53 and E2f: Partners in life and death. Nat. Rev. Cancer 9(10), 738–748 (2009).
Benosman, S. et al. Multiple neurotoxic stresses converge on MDMX proteolysis to cause neuronal apoptosis. Cell Death Differ. 14(12), 2047–2057 (2007).
Colacurcio, D. J., Yeager, A., Kolson, D. L., Jordan-Sciutto, K. L. & Akay, C. Calpain-mediated degradation of MDMx/MDM4 contributes to HIV-induced neuronal damage. Mol. Cell. Neurosci. 57, 54–62 (2013).
Sang, P. et al. Alpha-helix-mimicking sulfono-gamma-AApeptide inhibitors for p53-MDM2/MDMX protein–protein interactions. J. Med. Chem. 63(3), 975–986 (2020).
Uesato, S. et al. Discovery of new low-molecular-weight p53-Mdmx disruptors and their anti-cancer activities. Bioorg. Med. Chem. 24(8), 1919–1926 (2016).
Pulya, S. et al. HDAC6 as privileged target in drug discovery: A perspective. Pharmacol. Res. 163, 105274 (2021).
Picci, C. et al. HDAC6 inhibition promotes alpha-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice. Exp. Neurol. 328, 113281 (2020).
Chen, S., Owens, G. C., Makarenkova, H. & Edelman, D. B. HDAC6 regulates mitochondrial transport in hippocampal neurons. PLoS One 5(5), e10848 (2010).
LoPresti, P. HDAC6 in diseases of cognition and of neurons. Cells 10(1), 12 (2020).
English, K. & Barton, M. C. HDAC6: A key link between mitochondria and development of peripheral neuropathy. Front. Mol. Neurosci. 14, 684714 (2021).
LoPresti, P. The selective HDAC6 inhibitor ACY-738 impacts memory and disease regulation in an animal model of multiple sclerosis. Front. Neurol. 10, 519 (2019).
Zhao, Y., Liang, T., Hou, X. & Fang, H. Recent development of novel HDAC6 isoform-selective Inhibitors. Curr. Med. Chem. 28(21), 4133–4151 (2021).
Narita, K. et al. Synthesis and biological evaluation of novel FK228 analogues as potential isoform selective HDAC inhibitors. Eur. J. Med. Chem. 121, 592–609 (2016).
Hiranaka, S. et al. Design, synthesis, and blood–brain barrier transport study of pyrilamine derivatives as histone deacetylase inhibitors. ACS Med. Chem. Lett. 9(9), 884–888 (2018).
Nagano, S. et al. TDP-43 transports ribosomal protein mRNA to regulate axonal local translation in neuronal axons. Acta Neuropathol. 140(5), 695–713 (2020).
Miyoshi, H., Blomer, U., Takahashi, M., Gage, F. H. & Verma, I. M. Development of a self-inactivating lentivirus vector. J. Virol. 72(10), 8150–8157 (1998).
Yan, H. et al. MiRNA-132/212 regulates tight junction stabilization in blood-brain barrier after stroke. Cell Death Discov. 7(1), 380 (2021).
Garcia, J. H., Wagner, S., Liu, K. F. & Hu, X. J. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation. Stroke 26(4), 627–634 (1995) (discussion 35).
Watanabe, A. et al. Serine racemase inhibition induces nitric oxide-mediated neurovascular protection during cerebral ischemia. Neuroscience 339, 139–149 (2016).
Reed, D. et al. Identification and characterization of the first small molecule inhibitor of MDMX. J. Biol. Chem. 285(14), 10786–10796 (2010).
Hirata, Y. et al. New 5-aryl-substituted 2-aminobenzamide-type HDAC inhibitors with a diketopiperazine group and their ameliorating effects on ischemia-induced neuronal cell death. Sci. Rep. 8(1), 1400 (2018).
Strachan, G. D., Jordan-Sciutto, K. L., Rallapalli, R., Tuan, R. S. & Hall, D. J. The E2F–1 transcription factor is negatively regulated by its interaction with the MDMX protein. J. Cell. Biochem. 88(3), 557–568 (2003).
Sasaki, T. et al. SIK2 is a key regulator for neuronal survival after ischemia via TORC1-CREB. Neuron 69(1), 106–119 (2011).
Kiyokawa, S. et al. New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group. Bioorg. Med. Chem. 18(11), 3925–3933 (2010).
Maeda, T. et al. Potent histone deacetylase inhibitors: N-hydroxybenzamides with antitumor activities. Bioorg. Med. Chem. 12(16), 4351–4360 (2004).
Soussi, T., Ishioka, C., Claustres, M. & Beroud, C. Locus-specific mutation databases: Pitfalls and good practice based on the p53 experience. Nat. Rev. Cancer 6(1), 83–90 (2006).
Soussi, T. & Wiman, K. G. Shaping genetic alterations in human cancer: The p53 mutation paradigm. Cancer Cell 12(4), 303–312 (2007).
Sanz, G., Singh, M., Peuget, S. & Selivanova, G. Inhibition of p53 inhibitors: Progress, challenges and perspectives. J. Mol. Cell Biol. 11(7), 586–599 (2019).
Rodriguez, C. et al. Single-nucleotide polymorphism 309T>G in the MDM2 promoter determines functional outcome after stroke. Stroke 49(10), 2437–2444 (2018).
Migliorini, D. et al. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol. Cell. Biol. 22(15), 5527–5538 (2002).
Strachan, G. D., Koike, M. A., Siman, R., Hall, D. J. & Jordan-Sciutto, K. L. E2F1 induces cell death, calpain activation, and MDMX degradation in a transcription independent manner implicating a novel role for E2F1 in neuronal loss in SIV encephalitis. J. Cell. Biochem. 96(4), 728–740 (2005).
Huang, Q., Chen, L., Schonbrunn, E. & Chen, J. MDMX inhibits casein kinase 1alpha activity and stimulates Wnt signaling. EMBO J. 39(14), e104410 (2020).
Wohlberedt, K. et al. Mdm4 supports DNA replication in a p53-independent fashion. Oncogene 39(25), 4828–4843 (2020).
Venkatesh, D. et al. MDM2 and MDMX promote ferroptosis by PPARalpha-mediated lipid remodeling. Genes Dev. 34(7–8), 526–543 (2020).
Ding, H., Dolan, P. J. & Johnson, G. V. Histone deacetylase 6 interacts with the microtubule-associated protein tau. J. Neurochem. 106(5), 2119–2130 (2008).
Cook, C. et al. Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation. Hum. Mol. Genet. 21(13), 2936–2945 (2012).
Yee, A. J. et al. Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A multicentre phase 1b trial. Lancet Oncol. 17(11), 1569–1578 (2016).
Bitler, B. G. et al. ARID1A-mutated ovarian cancers depend on HDAC6 activity. Nat. Cell Biol. 19(8), 962–973 (2017).
Ryu, H. W. et al. HDAC6 deacetylates p53 at lysines 381/382 and differentially coordinates p53-induced apoptosis. Cancer Lett. 391, 162–171 (2017).